Holder exit: IO Biotech (NASDAQ: IOBT) reports zero shares owned

Rhea-AI Filing Summary

IO Biotech, Inc. reports that Reporting Person Jorey Chernett no longer beneficially owns any shares of common stock as of the close of business on May 19, 2026. The filing is an Amendment No. 2 to a Schedule 13G/A reflecting an exit filing.

The cover information lists the class as Common Stock, $0.001 par value (CUSIP 449778109). The signature block is dated 05/20/2026.

Insights

Equity Compliance Analyst

Exit filing shows zero beneficial ownership as of May 19, 2026.

The Schedule 13G/A amendment is an administrative ownership update: the Reporting Person states they "no longer beneficially owned any shares" of common stock as of the close of business on May 19, 2026. The filing is signed on 05/20/2026.

This change is presented as an ownership cessation rather than an explanatory transaction record; the filing does not state how the position was reduced. Subsequent filings or trading reports would show mechanics if disclosed.

Corporate Governance Specialist

Administrative ownership update with limited investor impact.

The document is labeled "Amendment No. 2" and explicitly describes the submission as an "exit filing" for the Reporting Person. It identifies the security class and CUSIP 449778109, confirming the update pertains to common stock.

Because this is a compliance disclosure of zero holdings, it is routine; any material market impact would require additional transactional detail or large-scale holder concentration information not present here.

Key Figures

Beneficial ownership: 0 shares Form type: Schedule 13G/A Amendment No. 2 CUSIP: 449778109 +1 more

4 metrics

Beneficial ownership 0 shares as of the close of business on <date>May 19, 2026</date>

Form type Schedule 13G/A Amendment No. 2 ownership amendment / exit filing

CUSIP 449778109 Common Stock, $0.001 par value

Signature date 05/20/2026 date signed by Reporting Person

Key Terms

exit filing, beneficially owned, CUSIP

3 terms

exit filing regulatory

"This Amendment No. 2 constitutes an exit filing for the Reporting Person"

beneficially owned regulatory

"the Reporting Person no longer beneficially owned any shares of Common stock"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

CUSIP financial

"CUSIP No.: 449778109"

A CUSIP is a nine-character alphanumeric code that uniquely identifies a U.S. or Canadian financial security—such as a stock, bond, or fund share—like a Social Security number for an investment. It matters to investors because brokers, exchanges and record-keepers use the CUSIP to match trades, track ownership, settle transactions and pull accurate records, reducing errors and ensuring money and securities go to the right place.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

IO Biotech, Inc.

(Name of Issuer)

Common Stock, $0.001 Par Value Per Share

(Title of Class of Securities)

449778109

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 449778109

1

Names of Reporting Persons

Chernett Jorey

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: This Amendment No. 2 constitutes an exit filing for the Reporting Person (as defined below), as the Reporting Person no longer beneficially owns any shares of the Issuer.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: IO Biotech, Inc.
(b)	Address of issuer's principal executive offices: OLE MAALOES VEH 3, COPENHAGEN, G7, 2200
Item 2.
(a)	Name of person filing: Jorey Chernett (the "Reporting Person")
(b)	Address or principal business office or, if none, residence: The principal business address of the Reporting Person is 6222 Indianwood Trail, Bloomfield Hills, MI 48301.
(c)	Citizenship: US
(d)	Title of class of securities: Common Stock, $0.001 Par Value Per Share
(e)	CUSIP No.: 449778109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: As of the close of business on May 19, 2026, the Reporting Person no longer beneficially owned any shares of Common stock, par value $0.001 per share, of the Issuer ("Shares").
(b)	Percent of class: As of the close of business on May 19, 2026, the Reporting Person no longer beneficially owned any Shares.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Cover Pages Items 5-9.
	(ii) Shared power to vote or to direct the vote: See Cover Pages Items 5-9.
	(iii) Sole power to dispose or to direct the disposition of: See Cover Pages Items 5-9.
	(iv) Shared power to dispose or to direct the disposition of: See Cover Pages Items 5-9.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Chernett Jorey

Signature:	/s/ Jorey Chernett
Name/Title:	Jorey Chernett
Date:	05/20/2026

FAQ

What does IO Biotech (IOBT) Schedule 13G/A Amendment No. 2 state?

It states that reporting person Jorey Chernett no longer beneficially owns any common shares as of May 19, 2026. The amendment is described as an "exit filing" and is signed on 05/20/2026, with CUSIP 449778109.

Does the filing specify how Jorey Chernett disposed of IOBT shares?

No, the Schedule 13G/A Amendment states only that the Reporting Person no longer beneficially owned any shares as of May 19, 2026. The filing does not disclose the method or transaction details that led to the zero holding.

What class of security is affected in the IOBT filing?

The filing pertains to Common Stock, $0.001 par value per share, identified by CUSIP 449778109. The ownership update applies to that class as of the close of business on May 19, 2026.

When was the Schedule 13G/A Amendment signed for IO Biotech (IOBT)?

The signature block shows Jorey Chernett signed the Amendment on 05/20/2026. The ownership status in Item 4 is dated as of the close of business on May 19, 2026.